2026 Critical Care Congress Skip to main content
2026 Critical Care Congress Main banner
Final Program


Advance Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Thought Leader Session
Thought Leader Session
Guidelines Session
Guidelines Session
Aging Adult Track
Aging Adult Track
Additional Registration Fee
Additional Registration Fee

Research Snapshot Theater: Future of Critical Care/Pulmonary, Adult II

Refractory Status Asthmaticus in a Patient on VV ECMO Augmented by Rescue Therapy With Omalizumab

Monday, March 23, 2026
10:15 AM - 11:15 AM Central Time
Location: Connections Central - RST 03
  • AA

    Atteh Akoto, MD

    Summa Health - Akron City Hospital

    Disclosure(s): No relevant financial relationship(s) to disclose.

  • HW

    Harrison Wood, DO

    Pulmonary and Critical Care Fellow
    Summa Health

    Disclosure information not submitted.

  • MC

    Michael Chandler, MD

    Pulmonary Critical Care Teaching Faculty and Critical Care Department Chair
    Akron City Hospital

    Disclosure information not submitted.

  • AR

    Aliaksandr Ramaniuk, DO

    Pulmonary and Critical Care Teaching Faculty
    Summa Health

    Disclosure information not submitted.

Introduction: Refractory status asthmaticus is a medical emergency with high risk for morbidity and mortality. For patients who fail standard ICU management, VV ECMO or inhaled anesthetics such as sevoflurane may be offered. There is growing numbers of case reports of “off label” or compassionate use of biologic agents such as anti-IGE omalizumab, anti-IL-5Ra benralizumab, and anti-TSLP tezepelumab. Prior to their use the indication, mechanism of action, risk/benefit, and pharmacodynamics of biologic therapies must be considered when used off label as rescue therapy. Here, we discuss a case of a patient with refractory status asthmaticus on VV ECMO who had improvement with off label use of omalizumab as rescue therapy.


Description: A 49 year-old male with PMH of asthma and COPD with established T2 high phenotype presents to the emergency department for shortness of breath. The patient failed a limited trial of NIV requiring intubation. Due to difficulty with ventilation and high airway pressures the patient was placed on VV ECMO. Despite five days on ECMO, the patient had persistent bronchospasm that did not response to bronchodilators and transiently improved with magnesium boluses. Outpatient labs demonstrated T2 high inflammatory phenotype with eosinophilia and IGE over 800. Due to this and his refractory respiratory status, he was given a dose of outpatient omalizumab 600 mg via subcutaneous injection off label for compassionate use. At 48 hours the patient’s dynamic compliance quintupled from 27 mL/cm H2O to 140 mL/cm H2O and by four days post treatment the patient's tidal volumes tripled from 150 mL to 450 mL. Nine days post treatment, the patient was de-cannulated from VV ECMO and extubated to supplemental oxygen. The patient was discharged home on room air five days later to follow up with pulmonology for his asthma.


Discussion: Our patient showed improved ventilation at 48 hours and was able to be extubated and decannulated at day 9, this is consistent with the limited established literature and tracks with omalizumab's onset of action of 7-8 days. Our case adds to the growing number of case reports describing the use of biologic agents in refractory status asthmaticus and is one of a handful of cases in a patient on VV ECMO.